Overview

Lamazym Aftercare Study

Status:
Active, not recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamazym i.v. treatment of subjects with alpha-Mannosidosis whom previously participated in Lamazym-trial.

Phase:

Phase 3

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.
Zymenex A/S